Estimating the Risk of ABO Hemolytic Disease of the Newborn in Lagos

Akanmu, AS; Oyedeji, Olufemi Abiola; Adeyemo, Titilope A.; Ogbenna, Ann Abiola

doi:10.1155/2015/560738

Cited by 25 publications

(22 citation statements)

References 19 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The predominant blood group in our study was type O and the least common was AB. This is consistent with studies in Nigeria, which also showed the predominant group to be O and the least common to be AB [ 27 ]. In Kenya, Uganda, Mauritania and Ethiopia similar studies also showed the predominant blood group to be O and the least prevalent to be AB [ 27 – 30 ].…”

Section: Main Textsupporting

confidence: 92%

“…This is consistent with studies in Nigeria, which also showed the predominant group to be O and the least common to be AB [ 27 ]. In Kenya, Uganda, Mauritania and Ethiopia similar studies also showed the predominant blood group to be O and the least prevalent to be AB [ 27 – 30 ]. These trends, in keeping with other studies, may suggest that blood group AB is the least dominant while O is the most dominant overall across the continent.…”

Section: Main Textsupporting

confidence: 92%

See 1 more Smart Citation

ABO and Rhesus blood group distribution and frequency among blood donors at Kilimanjaro Christian Medical Center, Moshi, Tanzania

et al. 2017

View full text Add to dashboard Cite

ObjectiveThis study aims to determine the distribution of blood groups and the demographic background of blood donors in a referral hospital in Northern Tanzania.ResultsThe most common blood group was O (52.3%) and the least common was AB (3.18%). 97.7% of the blood donors were Rh positive and the rest were Rh negative. Most donors were young adults, representing the age group of 19–29. The majority of donors were male (88.1%) and the majority (90.8%) were replacement while the remainder was voluntary donors.

show abstract

Section: Main Textsupporting

confidence: 92%

Section: Main Textsupporting

confidence: 92%

ABO and Rhesus blood group distribution and frequency among blood donors at Kilimanjaro Christian Medical Center, Moshi, Tanzania

et al. 2017

View full text Add to dashboard Cite

show abstract

“…ABO blood group-caused hemolytic disease of the fetus and newborn (HDFN) is very frequent but only rarely severe [1][2][3][4][5][6][7][8][9]. The ABO blood group system is the only system in which natural IgM antibodies against the corresponding antigens are universally present from a young age, at approximately 4 months.…”

Section: Introductionmentioning

confidence: 99%

Next Generation Sequencing-Based Fetal ABO Blood Group Prediction by Analysis of Cell-Free DNA from Maternal Plasma

Rieneck

Hother

Clausen

et al. 2020

Transfus Med Hemother

View full text Add to dashboard Cite

Introduction: ABO blood group incompatibility between a pregnant woman and her fetus as a cause of morbidity or mortality of the fetus or newborn remains an important, albeit rare, risk. When a pregnant woman has a high level of anti-A or anti-B IgG antibodies, the child may be at risk for hemolytic disease of the fetus and newborn (HDFN). Performing a direct prenatal determination of the fetal ABO blood group can provide valuable clinical information. Objective: Here, we report a next generation sequencing (NGS)based assay for predicting the prenatal ABO blood group. Materials and Methods: A total of 26 plasma samples from 26 pregnant women were tested from gestational weeks 12 to 35. Of these samples, 20 were clinical samples and 6 were test samples. Extracted cell-free DNA was PCR-amplified using 2 primer sets followed by NGS. NGS data were analyzed by 2 different methods, FASTQ analysis and a grep search, to ensure robust results. The fetal ABO prediction was compared with the known serological infant ABO type, which was available for 19 samples. Results: There was concordance for 19 of 19 predictable samples where the phenotype information was available and when the analysis was done by the 2 methods. For immunized pregnant women (n = 20), the risk of HDFN was predicted for 12 fetuses, and no risk was predicted for 7 fetuses; one result of the clinical samples was indeterminable. Cloning and sequencing revealed a novel variant harboring the same single nucleotide variations as ABO*O.01.24 with an additional c.220C>T substitution. An additional indeterminable result was found among the 6 test samples and was caused by maternal heterozygosity. The 2 indeterminable samples demonstrated limitations to the assay due to hybrid ABO genes or maternal heterozygosity. Conclusions: We pioneered an NGS-based fetal ABO prediction assay based on a cell-free DNA analysis from maternal plasma and demonstrated its application in a small number of samples. Based on the calculations of variant frequencies and ABO*O.01/ABO*O.02 heterozygote frequency, we estimate that we can assign a reliable fetal ABO type in approximately 95% of the forthcoming clinical samples of type O pregnant women. Despite the vast genetic variations underlying the ABO blood groups, many variants are rare, and prenatal ABO prediction is possible and adds valuable early information for the prevention of ABO HDFN.

show abstract

“…ABO incompatibility, one of the main causes of hemolytic disease in newborns, 18 has been well documented to be associated with the incidence and severity of neonatal hyperbilirubinemia. 7,19 It is estimated that 27% of newborns have ABO incompatibility in China, while only 15% worldwide. 20 Indeed, ABO hemolytic disease is regarded as an important factor in neonatal hyperbilirubinemia in East Asia.…”

Section: Discussionmentioning

confidence: 99%

UGT1A1 Mutation Association with Increased Bilirubin Levels and Severity of Unconjugated Hyperbilirubinemia in ABO Incompatible Newborns of China

Yang

Lin

Chen

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Neonatal hyperbilirubinemia causing jaundice is common in East Asian population. Uridine diphosphate glucuronosyltransferase isoenzyme (UGT1A1) glucuronidates bilirubin and converts the toxic form of bilirubin to its nontoxic form.Method: A retrospective study was conducted to review clinical information of ABO hemolysis neonates (ABO HDN) admitted to the Department of Neonatology, referred for neonatal hyperbilirubinemia, in a large general hospital of southern China from 2011 to 2017. Variation status of UGT1A1 was determined by direct sequencing or genotype assays.Result: Sixty-nine ABO HDNs were included into the final analysis. UGT1A1 c.211 G>A mutation (UGT1A1*6, p.Arg71Gly, rs4148323) was significantly associated with the increased bilirubin level in ABO HDNs, after adjusted by age, sex and feeding method (P=0.019 for TBIL, P=0.021 for IBIL). Moreover, heterozygous and/or homozygous UGT1A1 mutations in the coding sequence region were significantly associated with the increased risk of developing hazardous hyperbilirubinemia (as defined by TSB>427 umol/L) as compared those with a normal UGT1A1 genotype (ORadj=9.16, 95%CI 1.99- 42.08, P=0.002) in the study cohort.Conclusion: UGT1A1 variant in coding region is actively involved in the pathogenesis of ABO hemolysis related neonatal hyperbilirubinemia. Genetic assessment of UGT1A1 may be useful for clinical diagnosis of neonatal unconjugated hyperbilirubinemia.

show abstract

Estimating the Risk of ABO Hemolytic Disease of the Newborn in Lagos

Cited by 25 publications

References 19 publications

ABO and Rhesus blood group distribution and frequency among blood donors at Kilimanjaro Christian Medical Center, Moshi, Tanzania

ABO and Rhesus blood group distribution and frequency among blood donors at Kilimanjaro Christian Medical Center, Moshi, Tanzania

Next Generation Sequencing-Based Fetal ABO Blood Group Prediction by Analysis of Cell-Free DNA from Maternal Plasma

UGT1A1 Mutation Association with Increased Bilirubin Levels and Severity of Unconjugated Hyperbilirubinemia in ABO Incompatible Newborns of China

Contact Info

Product

Resources

About